These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34622871)

  • 1. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.
    Scriven YA; Mulinge MM; Saleri N; Luvai EA; Nyachieo A; Maina EN; Mwau M
    Medicine (Baltimore); 2021 Oct; 100(40):e27460. PubMed ID: 34622871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age and CD4+ T cell counts are inversely associated with HIV drug resistance mutations in treatment naive female sex workers.
    Mulinge MM; Oluoch JO; Abisi HK; Otieno LE; Anzala O; Wamalwa DC; Nduati RW; Kimani J; Herbeck J; McKinnon L
    Medicine (Baltimore); 2023 Jun; 102(24):e34060. PubMed ID: 37327289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
    Makwaga O; Adhiambo M; Mulama DH; Muoma J; Adungo F; Wanjiku H; Ongaya A; Maitha GM; Mwau M
    Pan Afr Med J; 2020; 37():311. PubMed ID: 33654530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis.
    Kinyua JG; Lihana RW; Kiptoo M; Muasya T; Odera I; Muiruri P; Songok EM
    Pan Afr Med J; 2018; 29():186. PubMed ID: 30061964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape Verde.
    Gonçalves P; Barreto J; Santos M; Leal S; Marcelino J; Abecasis A; Palladino C; Taveira N
    AIDS; 2024 Jul; 38(8):1101-1110. PubMed ID: 38349224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
    Deletsu SD; Maina EK; Quaye O; Ampofo WK; Awandare GA; Bonney EY
    Medicine (Baltimore); 2020 Feb; 99(7):e18777. PubMed ID: 32049783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.
    Deng X; Liu J; Li J; Yang B; Shu Y; Zhang M; Dong X
    AIDS Res Hum Retroviruses; 2020 May; 36(5):389-398. PubMed ID: 31914782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
    Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S
    J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
    Orrell C; Walensky RP; Losina E; Pitt J; Freedberg KA; Wood R
    Antivir Ther; 2009; 14(4):523-31. PubMed ID: 19578237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct drug resistance profile of HIV-1 subtype A strain circulating in Georgia.
    Dvali N; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2015 Mar; (240):19-24. PubMed ID: 25879553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
    Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
    BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Resistance Mutations in a Population Before Antiretroviral Therapy Initiation in Northern South Africa.
    Ogola B; Matume ND; Mavhandu-Ramarumo LG; Tebit DM; Bessong PO
    AIDS Res Hum Retroviruses; 2022 Mar; 38(3):248-256. PubMed ID: 34107774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana.
    Nii-Trebi NI; Brandful JAM; Ibe S; Sugiura W; Barnor JS; Bampoh PO; Yamaoka S; Matano T; Yoshimura K; Ishikawa K; Ampofo WK
    J Med Microbiol; 2017 Nov; 66(11):1663-1672. PubMed ID: 29068286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).
    Parikh UM; Kiepiela P; Ganesh S; Gomez K; Horn S; Eskay K; Kelly C; Mensch B; Gorbach P; Soto-Torres L; Ramjee G; Mellors JW;
    PLoS One; 2013; 8(4):e59787. PubMed ID: 23585827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.